Search company, investor...

ViroChem Pharma

virochempharma.com

Stage

Acquired | Acquired

Valuation

$0000 

About ViroChem Pharma

ViroChem Pharma Inc focuses on the discovery and development of antiviral therapeutic agentsi¿½ The company is productoriented and RD basedi¿½ Its strategy is to maintain a resultoriented equilibrium between risk and probability of success by focusing selectively on druggable biological targets that are well validated with small molecule leads but do not yet have adequate drug therapies in the market

Headquarters Location

275 Armand-Frappier Boulvard

Laval, Quebec, QC H7V 4A7,

Canada

Missing: ViroChem Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ViroChem Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest ViroChem Pharma News

Vertex buys ViroChem in $375M in hep C deal - FierceBiotech

Jul 31, 2013

Reprint With its closely-watched hep C drug telaprevir working its way toward an FDA filing, Vertex Pharmaceuticals announced that it is buying Canada's ViroChem Pharma for $375 million in cash and stock. The deal gives Vertex access to two pipeline drugs that could offer a big assist in creating cocktail therapeutics for hep C patients. Vertex will pay $100 million in cash and issue $275 million in shares for the acquisition. Vertex has achieved widespread interest in its telaprevir  program, which promises to be a blockbuster therapy offering patients a first-line therapy with better efficacy than currently used drugs. But as Xconomy notes, there are a host of other hep C drugs in the pipeline. Many of those drugs will help create new cocktail drugs that can work even better as a combo therapy, much like HIV cocktails do today. And that inspired Vertex to buy the Canadian developer. "These compounds look as good as anything we've seen, and better than most. And we've looked at everything," CEO Josh Boger told analysts. One of ViroChem's drugs, VCH-222, produced what Vertex called "the most substantial reduction" of the virus for any solo polymerase inhibitor drug being studied. - read the report from Xconomy Related Articles:

ViroChem Pharma Frequently Asked Questions (FAQ)

  • Where is ViroChem Pharma's headquarters?

    ViroChem Pharma's headquarters is located at 275 Armand-Frappier Boulvard, Laval.

  • What is ViroChem Pharma's latest funding round?

    ViroChem Pharma's latest funding round is Acquired.

  • Who are the investors of ViroChem Pharma?

    Investors of ViroChem Pharma include Vertex Pharmaceuticals, Fonds de Solidarite FTQ, Caisse de depot et placement du Quebec and BDC Healthcare Venture Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.